Physician profile
Maria D Markiewicz
NPI 1144293853
$7,687.25
in general payments reported to CMS, 2019-2025
32 companies · $1,176 in 2025
The $1,176 reported for 2025 was more than what 88% of Foot Surgery providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,455 · 2020: $737 · 2021: $1,006 · 2022: $553 · 2023: $1,998 · 2024: $762 · 2025: $1,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,106 · Travel and Lodging: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,106.13 |
| Travel and Lodging | $830.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $3,041.26 | 2019-2025 | Variax, Axsos, Gamma |
| Organogenesis INC. | $1,095.25 | 2019-2025 | Affinity, Puraply Wound Matrix, Puraply |
| Horizon Therapeutics Plc | $551.80 | 2019-2023 | Krystexxa |
| Smith+Nephew, INC. | $435.62 | 2019-2022 | |
| Wright Medical Technology, INC. | $407.90 | 2019 | |
| Medical Device Business Services, INC. | $401.57 | 2021 | |
| Convatec INC. | $268.91 | 2023-2025 | |
| Paratek Pharmaceuticals, INC. | $247.07 | 2020-2025 | Nuzyra |
| Depuy Synthes Sales INC. | $162.82 | 2021-2025 | Motoband |
| Treace Medical Concepts, INC. | $158.56 | 2022-2025 | |
| Trilliant Surgical LLC. | $140.43 | 2020 | |
| Amgen INC. | $104.10 | 2024-2025 | Krystexxa |
| Ibsa Pharma INC. | $103.11 | 2023 | Tirosint, Licart |
| Abbvie INC. | $77.03 | 2021-2023 | |
| Kci USA, INC. | $53.65 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $53.10 | 2024-2025 | Qutenza |
| Abbott Laboratories | $42.08 | 2019-2022 | |
| Zyla Life Sciences, INC. | $40.46 | 2019 | |
| Kerecis Limited | $38.46 | 2019-2021 | |
| Forte Bio-Pharma LLC | $28.00 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $27.83 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.27 | 2023 | Seglentis |
| Saluda Medical Americas, INC. | $26.00 | 2025 | Evoke |
| Trevena, INC. | $22.77 | 2022 | |
| Baudax Bio INC. | $22.14 | 2020 | |
| Sebela Pharmaceuticals INC. | $19.26 | 2020 | |
| Bioventus LLC | $18.39 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $15.77 | 2020 | |
| Melinta Therapeutics, LLC | $15.04 | 2019 | |
| Reprise Biomedical, INC. | $14.53 | 2024 | Miro3d |
| Musculoskeletal Transplant Foundation INC. | $14.07 | 2021 | |
| Celularity INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Markiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.